ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Multiple Myeloma

Multiple Myeloma

The US Food and Drug Administration (FDA) placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma: KEYNOTE-183, KEYNOTE-185, and KEYNOT

Treatment with the combination of daratumumab plus pomalidomide/dexamethasone resulted in rapid, deep, and sustained responses with no new safety signals in patients with heavily treated multiple myeloma.

Undergoing autologous hematopoietic stem cell transplantation was effective and safe in patients with refractory multiple myeloma, including those patients who are refractory to both proteasome inhibitors and immunomodulatory agents.

The FDA has approved daratumumab in combination with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma.

Combining bendamustine, pomalidomide, and dexamethasone achieved a promising overall response rate in patients with heavily pretreated lenalidomide refractory multiple myeloma, according to the results of a phase I/II trial.

In this peer-to-peer discussion two experts discuss the nuances and challenges of treating elderly patients with myeloma, and why therapies need to be tailored based on frailty status rather than age.

In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.